# Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

> **NCT02603809** · PHASE2 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 1659 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Aprocitentan 5 mg
- **DRUG:** Aprocitentan 10 mg
- **DRUG:** Aprocitentan 25 mg
- **DRUG:** Aprocitentan 50 mg
- **DRUG:** Lisinopril 20 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02603809
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-14
- **Primary completion:** 2017-02-28
- **Final completion:** 2017-04-07
- **Target enrollment:** 1659 (ACTUAL)
- **Last updated:** 2022-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02603809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02603809, "Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02603809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*